Neovascular Age-Related Macular Degeneration: Emerging Therapies With an EY...

Event Information

Share this event

Date and Time



Hyatt Regency Chicago

151 East Wacker Drive

Plaza Ballroom; East Tower, Lobby Level

Chicago, Illinois 60601

View Map

Event description


This program is intended for American Society of Retina Specialists Annual Meeting attendees only.

Activity Chair

Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, NV


Diana V. Do, MD
Vice Chair for Clinical Affairs
Professor of Ophthalmology
Byers Eye Institute
Stanford University School of Medicine
Palo Alto, CA

Michael A. Singer, MD
Director of Clinical Research
Medical Center Ophthalmology Associates
Clinical Professor
University of Texas Health Science Center
San Antonio, TX


The treatment of neovascular age-related macular degeneration (nAMD) has been revolutionized through the introduction of intravitreal anti–vascular endothelial growth factor (anti-VEGF) therapy into management protocols. Maintenance of initial visual acuity gains requires continued intravitreal injections leading to treatment burden for the patient. Evaluation and modification of treatment protocols, along with new delivery systems and novel anti-VEGF therapies have the potential to provide long-term visual acuity gains while reducing treatment burden. In this live satellite symposium, experts in the field will discuss the current burden of treatment, evaluate new dosing and administration schedules, as well as review the safety and efficacy of therapies in late-stage development that have the potential to reduce treatment frequency in the management of nAMD.


10:45 AM
Registration and Lunch

11:15 AM
Introduction and Pretest
Arshad M. Khanani, MD, MA

11:20 AM
Re-thinking the Burden of Treatment in nAMD
Michael A. Singer, MD

11:35 AM
Rapid-Fire Roundtable: Burden of Injections in nAMD

11:40 AM
Evaluating New Mechanisms for Delivery of Agents for nAMD
Diana V. Do, MD

11:55 AM
Rapid-Fire Roundtable: Delivery of nAMD Treatment - New Methods and Mechanisms

12:05 PM
Comparing the Latest Evidence – Reducing Treatment Burden
Arshad M. Khanani, MD, MA

12:20 PM
Rapid-Fire Roundtable: Comparing Clinical Trial Outcomes for Late-Stage nAMD Treatments

12:30 PM

12:35 PM
Question and Answer

12:45 PM

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden associated with the conventional use of anti-VEGF agents in the treatment of nAMD.

  • Assess new dosing and administration schedules for the treatment of nAMD that may reduce injection frequency while maintaining visual acuity.

  • Analyze new evidence pertaining to the safety and efficacy of therapies in late-stage development for the management of nAMD.

Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with nAMD.

This continuing medical education activity is provided by Vindico Medical Education.

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

This program is not affiliated with ASRS.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support,all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.

Share with friends

Date and Time


Hyatt Regency Chicago

151 East Wacker Drive

Plaza Ballroom; East Tower, Lobby Level

Chicago, Illinois 60601

View Map

Save This Event

Event Saved